Current Drug Metabolism - Volume 12, Issue 5, 2011

Drug metabolic enzyme is a key factor to determine the intracorporal processes of drugs. The polymorphism of the drug metabolic enzymes affects almost 30% of the drug metabolism; some susceptibility genes of a disease will be possibly found though systematic analysis of these SNPs. As SNPs may determine the tiny difference between the gene sequences of an individual and a group of people, the researches on SNPs Read More

This review focuses on identification of the important active site residues of CYP2D6 in terms of CYP2D6 polymorphism. A meta-analysis was performed on the reported literature regarding (1) values of the Michaelis-Menten constant (Km), maximal velocity (Vmax), and intrinsic clearance (Vmax/Km) for 41 metabolic reactions of 31 substrates mediated by human cytochrome P450 2D6 and its variants and mutants and (2) i Read More

Among all the drug metabolic enzymes, cytochrome P450 (CYP450) superfamily acts as an important role responsible for the oxidation of almost 90% currently used drugs. As variations of Single Nucleotide Polymorphism (SNPs) in human CYP450 genes will cause different drug effects and even adverse effects, studies on SNPs of human CYP450 genes can be used for indicating the most possible genes associated with huma Read More

The Human Genome and the Hap Map Projects as well as the extensive use of deep resequencing worldwide, have contributed to a massive catalogue of reported single nucleotide polymorphisms (SNPs) and other genetic variations in the human genome. Pharmacogenomics is an emerging field that combines genetics with pharmacokinetics and pharmacodynamics of the drug in attempt to understand inter-individ Read More

The association between gene expression and clinical characteristics of non-small cell lung cancer (NSCLC) are uncovered. These genes are critical elements in carcinoma physiological processes, including DNA synthesis, DNA repair and mitosis. Genes such as ERCC1, RRM1, TYMS, TUBB3 and STMN1 are predictive biomarker candidates for chemotherapy sensitivity in patients with NSCLC. Suitable gene expression analyzing tec Read More

Over 10 million SNPs have been discovered to date as the result of both a private and public effort in the past two decades. Extensive investigations on SNPs have been performed to assess clinical applications for pharmacogenomics and Personalized Medicine. Recently, around the 10th anniversary of the first publication by the Human Genome Project, Hamburg and Collins addressed questions regarding the progress of t Read More

In the field of pharmacogenetics, we currently have a few markers to guide physicians as to the best course of therapy for patients. For the most part, these genetic variants are within a drug metabolizing enzyme that has a large effect on the degree or rate at which a drug is converted to its metabolites. For many drugs, response and toxicity are multi-genic traits and understanding relationships between a patient's genetic va Read More

Single Nucleotide Polymorphisms (SNPs) are the most abundant form of genetic variations observed in the human genome. With the advent of high-throughput genotyping arrays and next-generation sequencing (NGS) platforms, tens of millions of SNPs have been uncovered in several human populations. However, the huge amount of SNPs bring new challenges in subsequent analysis. In reality, a number of SNPs may Read More